KR20230165285A - Gdf15 신호전달의 치료적 억제제 - Google Patents

Gdf15 신호전달의 치료적 억제제 Download PDF

Info

Publication number
KR20230165285A
KR20230165285A KR1020237037287A KR20237037287A KR20230165285A KR 20230165285 A KR20230165285 A KR 20230165285A KR 1020237037287 A KR1020237037287 A KR 1020237037287A KR 20237037287 A KR20237037287 A KR 20237037287A KR 20230165285 A KR20230165285 A KR 20230165285A
Authority
KR
South Korea
Prior art keywords
seq
domain
quel
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237037287A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 오라힐리
앤서니 패트릭 콜
아이린 시미노
에-치앙 리
후이 리우
아담 카펜터
Original Assignee
캠브리지 엔터프라이즈 리미티드
키맵 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104556.2A external-priority patent/GB202104556D0/en
Priority claimed from GBGB2107331.7A external-priority patent/GB202107331D0/en
Priority claimed from GBGB2108170.8A external-priority patent/GB202108170D0/en
Application filed by 캠브리지 엔터프라이즈 리미티드, 키맵 리미티드 filed Critical 캠브리지 엔터프라이즈 리미티드
Publication of KR20230165285A publication Critical patent/KR20230165285A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020237037287A 2021-03-31 2022-03-31 Gdf15 신호전달의 치료적 억제제 Pending KR20230165285A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2104556.2A GB202104556D0 (en) 2021-03-31 2021-03-31 Therapeutic inhibitors of GDF15 signalling
GB2104556.2 2021-03-31
GB2107331.7 2021-05-21
GBGB2107331.7A GB202107331D0 (en) 2021-05-21 2021-05-21 Therapeutic inhibitors of GDF15 signalling
GBGB2108170.8A GB202108170D0 (en) 2021-06-08 2021-06-08 Theraputic inhibitors of GDF15 Signalling
GB2108170.8 2021-06-08
PCT/EP2022/058669 WO2022207846A1 (en) 2021-03-31 2022-03-31 Therapeutic inhibitors of gdf15 signalling

Publications (1)

Publication Number Publication Date
KR20230165285A true KR20230165285A (ko) 2023-12-05

Family

ID=81580347

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037287A Pending KR20230165285A (ko) 2021-03-31 2022-03-31 Gdf15 신호전달의 치료적 억제제

Country Status (11)

Country Link
US (1) US20240182585A1 (enExample)
EP (1) EP4314071A1 (enExample)
JP (1) JP2024511853A (enExample)
KR (1) KR20230165285A (enExample)
AU (1) AU2022251923A1 (enExample)
BR (1) BR112023020152A2 (enExample)
CA (1) CA3215737A1 (enExample)
CO (1) CO2023013791A2 (enExample)
IL (1) IL307382A (enExample)
MX (1) MX2023011655A (enExample)
WO (1) WO2022207846A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
ES2518865T3 (es) 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CA2783934A1 (en) 2009-12-11 2011-06-16 Genecode As Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
PT2900263T (pt) 2012-09-26 2019-07-29 Univ Wuerzburg J Maximilians Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15)
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
EP3122775B1 (en) 2014-03-26 2019-11-13 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HUE054670T2 (hu) 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
JP6925326B2 (ja) 2015-10-02 2021-08-25 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
JP2019510739A (ja) * 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
AU2017228489A1 (en) 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途

Also Published As

Publication number Publication date
WO2022207846A1 (en) 2022-10-06
EP4314071A1 (en) 2024-02-07
BR112023020152A2 (pt) 2023-11-14
CO2023013791A2 (es) 2024-01-25
MX2023011655A (es) 2023-10-11
IL307382A (en) 2023-11-01
JP2024511853A (ja) 2024-03-15
CA3215737A1 (en) 2022-10-06
US20240182585A1 (en) 2024-06-06
AU2022251923A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
KR102473028B1 (ko) 항-tim-3 항체 및 조성물
AU2022204078B2 (en) Combination therapies targeting PD-1, TIM-3, and LAG-3
RU2755503C2 (ru) Анти-lag-3 антитела и их композиции
CN109689688B (zh) 抗icos抗体
US20090324602A1 (en) Anti-fn14 antibodies and uses thereof
TW200911833A (en) Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
PT2711375T (pt) Proteínas humanas de ligação a antigénios que se ligam a beta-klotho, recetores fgf e os seus complexos
TW201125581A (en) Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
KR20170105558A (ko) 항 alk2 항체
KR20230113295A (ko) Sars-cov-2에 대한 항체 및 그의 용도
CN115380049B (zh) 对生理性铁过载的治疗
KR20210068065A (ko) 안타고니스트
DK2373335T3 (en) Monoclonal anti-ferroportin 1 antibodies and uses thereof
KR20220131293A (ko) 항-e-셀렉틴 항체, 조성물 및 사용 방법
KR20240017054A (ko) 항-icos 항체를 사용한 pd-l1 음성 또는 저발현 암의 치료
KR20240019295A (ko) 인간화 항-clec-1a 항체 및 이의 항원 결합 단편 및 이의 모방체
CN117916262A (zh) Gdf15信号传导的治疗性抑制剂
RU2839429C2 (ru) Антагонисты
KR20240007760A (ko) 항-icos 항체의 용도
KR102968398B1 (ko) Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
RU2795232C2 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
HK40082642A (en) Combination therapies targeting pd-1, tim-3, and lag-3
KR20210105396A (ko) 안타고니스트
HK40082642B (zh) 靶向pd-1、tim-3及lag-3的组合疗法
HK40003736B (en) Anti-icos antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231030

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250204

Comment text: Request for Examination of Application